
Real-world DME care falls short from missed anti-VEGF loading; sustained delivery, neuroprotection, and better primary care coordination promise gains.
Rahul Khurana, MD, is partner and president/CEO of Northern California Retina Vitreous Associates and volunteer clinical associate professor in ophthalmology at the University of California, San Francisco.

Real-world DME care falls short from missed anti-VEGF loading; sustained delivery, neuroprotection, and better primary care coordination promise gains.

Real-world diabetic macular edema care lags trials as fewer VEGF injections and step therapy limit outcomes.